Tudor Investment Corp
ONCR

Tudor Investment Corp’s Oncorus, Inc. ONCR Stock Holding History

Tudor Investment Corp’s Portfolio ONCR Stock Details ONCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-56,311
Closed -$784K – 2061
2021
Q1 		$784K Buy
+56,311
New +$1.17M 0.02% 957

Other funds holding ONCR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tudor Investment Corp's ONCR Position: Q2 2021 in Review

Tudor Investment Corp sold out of Oncorus, Inc. (ONCR) in Q2 2021, closing a stake of 56,311 shares — an estimated $784K sold.

Tudor Investment Corp first reported a position in ONCR in Q1 2021 and held it in 1 quarter. The position peaked at $784K in Q1 2021. 50 funds tracked by Wall St. Rank hold ONCR as of Q2 2021.

  • Tudor Investment Corp reported no remaining Oncorus, Inc. position as of Q2 2021 after selling out during the quarter.
  • Tudor Investment Corp sold 56,311 Oncorus, Inc. shares in Q2 2021, an estimated $784K.
  • Tudor Investment Corp first reported a position in Oncorus, Inc. in Q1 2021 and held it in 1 quarter.
  • Tudor Investment Corp's Oncorus, Inc. position peaked at $784K in Q1 2021.
  • 50 funds tracked by Wall St. Rank held Oncorus, Inc. as of Q2 2021.

Based on Tudor Investment Corp's 13F filing for Q2 2021, filed 16 Aug 2021.